All articles tagged with #diabetesmedication
The practice of 'microdosing' Ozempic, a diabetes medication, is gaining popularity as a weight loss strategy. Originally intended for managing blood sugar levels in type 2 diabetes patients, Ozempic's active ingredient, semaglutide, has been found to aid in weight reduction. This off-label use raises concerns about potential side effects and the ethical implications of using a medication for non-prescribed purposes.
A comprehensive U.S. study has found that Novo Nordisk's diabetes and obesity medications, Ozempic and Wegovy, which contain the active ingredient semaglutide, are not associated with an increase in suicidal thoughts. Contrarily, the study, which analyzed electronic medical records of over 1.8 million patients, indicated a lower risk of new and recurrent suicidal thoughts among users of semaglutide compared to those on other weight loss or diabetes drugs. This research may alleviate concerns raised by previous reports and regulatory investigations into the potential mental health side effects of GLP-1 agonist drugs like semaglutide.
The FDA is reviewing side effects reported with GLP-1 receptor agonists like Ozempic, Mounjaro, and Wegovy, used for diabetes and weight loss. Side effects under investigation include hair loss, suicidal thoughts, and aspiration. While the FDA has not established a causal relationship between the drugs and these risks, they are assessing the need for regulatory actions such as label changes. Patients are advised to consult healthcare providers about concerns, and the FDA continues to monitor drug safety post-approval. Novo Nordisk and Eli Lilly, manufacturers of these drugs, emphasize patient safety and are cooperating with the FDA.
The FDA is investigating reports of hair loss and suicidal thoughts among users of GLP-1 receptor agonists, a class of drugs used for diabetes and weight loss, including brands like Ozempic, Mounjaro, and Wegovy. While these side effects have been reported to the FDA's Adverse Event Reporting System, the agency has not yet established a causal relationship between the drugs and the risks. The FDA continues to monitor drug safety post-approval and may take actions such as updating labels or implementing risk strategies if necessary. Novo Nordisk, a manufacturer of these drugs, has stated their commitment to patient safety and ongoing collaboration with the FDA.
Tirzepatide and semaglutide are both FDA-approved medications for weight loss, with tirzepatide showing better results in studies. Tirzepatide, also known as Mounjaro for diabetes and Zepbound for weight loss, targets two receptors, potentially offering an advantage over semaglutide, which targets one. However, individual responses vary, and factors like side effects, cost, insurance coverage, and availability due to shortages must be considered. Consultation with a healthcare provider is essential to determine the best option for weight loss on an individual basis.
Tirzepatide, known as Mounjaro for diabetes and Zepbound for weight loss, and semaglutide, known as Ozempic for diabetes and Wegovy for weight loss, are both FDA-approved medications that aid in weight loss. Tirzepatide, which targets two receptors, has shown better weight loss results in studies compared to semaglutide, but individual responses can vary. Factors such as side effects, insurance coverage, cost, and availability due to shortages must be considered before choosing a medication. Consultation with a healthcare provider is essential to determine the most suitable option for weight loss treatment.
A 38-year-old man developed gastroparesis, a condition causing stomach paralysis, after taking two doses of Mounjaro, a diabetes medication also used for weight loss. He has filed a lawsuit against the drugmaker Eli Lilly, alleging that he was not adequately warned about the potential for serious, lifelong stomach issues. The law firm representing him, Morgan & Morgan, is investigating over 10,000 potential cases of gastroparesis linked to GLP-1 class drugs like Mounjaro. The man's condition has significantly impacted his diet, work life, and overall well-being.